Risk Factors for Cognitive Decline in Persons with HIV

Overview

Journal Curr Opin Infect Dis

Specialty Infectious Diseases

Date 2024 Dec 6

PMID 39641182

Authors

Merle Henderson

Alan Winston

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Cognitive disorders persist in persons with HIV, despite virologically suppressive antiretroviral therapy. We summarize the current evidence on risk factors for cognitive decline in persons with HIV in the modern antiretroviral therapy-era.

Recent Findings: Recent consensus recommendations have proposed a new approach for defining cognitive impairment in persons with HIV, which distinguishes true cognitive impairment from low cognitive performance alone and considers both HIV and non-HIV-associated causes of brain injury. Adverse mental health, risks associated with substance misuse, and an increasing burden of age-related comorbidities have been highlighted as important contributors toward cognitive decline in this population. Aging may potentiate these risk factors through polypharmacy and drug-drug interactions.

Summary: Cognitive decline in persons with HIV is likely multifactorial, with contributions from both HIV and non-HIV-associated mechanisms, particularly age-related comorbidities. With an aging community of persons with HIV, screening for risk factors associated with cognitive decline may be crucial to implement appropriate risk reduction strategies.

References

Womack J, Murphy T, Leo-Summers L, Bates J, Jarad S, Gill T . Assessing the contributions of modifiable risk factors to serious falls and fragility fractures among older persons living with HIV. J Am Geriatr Soc. 2023; 71(6):1891-1901. PMC: 10258163. DOI: 10.1111/jgs.18304. View

Hauser K, Ohene-Nyako M, Knapp P . Accelerated brain aging with opioid misuse and HIV: New insights on the role of glially derived pro-inflammation mediators and neuronal chloride homeostasis. Curr Opin Neurobiol. 2022; 78:102653. PMC: 9933139. DOI: 10.1016/j.conb.2022.102653. View

Chow F, Mundada N, Abohashem S, La Joie R, Iaccarino L, Arechiga V . Psychological stress is associated with arterial inflammation in people living with treated HIV infection. Brain Behav Immun. 2023; 113:21-28. DOI: 10.1016/j.bbi.2023.06.019. View

Chow F, Nance R, Becker K, Ho E, Huffer A, Kalani R . Sex Differences in the Risk of Stroke Associated With Traditional and Non-Traditional Factors in a US Cohort of People With HIV Infection. Neurology. 2024; 103(4):e209726. PMC: 11793864. DOI: 10.1212/WNL.0000000000209726. View

Woods S, Teixeira A, Martins L, Fries G, Colpo G, Rocha N . Accelerated epigenetic aging in older adults with HIV disease: associations with serostatus, HIV clinical factors, and health literacy. Geroscience. 2023; 45(4):2257-2265. PMC: 10651616. DOI: 10.1007/s11357-023-00759-9. View

Ambrosioni J, Levi L, Alagaratnam J, van Bremen K, Mastrangelo A, Waalewijn H . Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023. HIV Med. 2023; 24(11):1126-1136. DOI: 10.1111/hiv.13542. View

Doctor J, Winston A, Vera J, Post F, Boffito M, Mallon P . Anticholinergic medications associated with falls and frailty in people with HIV. HIV Med. 2023; 24(12):1198-1209. DOI: 10.1111/hiv.13532. View

Heaton R, Ellis R, Tang B, Marra C, Rubin L, Clifford D . Twelve-year neurocognitive decline in HIV is associated with comorbidities, not age: a CHARTER study. Brain. 2022; 146(3):1121-1131. PMC: 10169412. DOI: 10.1093/brain/awac465. View

Rakshasa-Loots A, Bakewell N, Sharp D, Gisslen M, Zetterberg H, Alagaratnam J . Biomarkers of central and peripheral inflammation mediate the association between HIV and depressive symptoms. Transl Psychiatry. 2023; 13(1):190. PMC: 10244452. DOI: 10.1038/s41398-023-02489-0. View

10.

Wang C, Schlub T, Yu W, Tan C, Stefic K, Gianella S . Landscape of Human Immunodeficiency Virus Neutralization Susceptibilities Across Tissue Reservoirs. Clin Infect Dis. 2022; 75(8):1342-1350. PMC: 9555844. DOI: 10.1093/cid/ciac164. View

11.

Antinori A, Arendt G, Becker J, Brew B, Byrd D, Cherner M . Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007; 69(18):1789-99. PMC: 4472366. DOI: 10.1212/01.WNL.0000287431.88658.8b. View

12.

Navia B, Jordan B, Price R . The AIDS dementia complex: I. Clinical features. Ann Neurol. 1986; 19(6):517-24. DOI: 10.1002/ana.410190602. View

13.

Samboju V, Cobigo Y, Paul R, Naasan G, Hillis M, Tsuei T . Cerebrovascular Disease Correlates With Longitudinal Brain Atrophy in Virally Suppressed Older People Living With HIV. J Acquir Immune Defic Syndr. 2021; 87(4):1079-1085. PMC: 8547347. DOI: 10.1097/QAI.0000000000002683. View

14.

Qu Y, Weinstein A, Wang Z, Cheng Y, Kingsley L, Levine A . Legacy effect on neuropsychological function in HIV-infected men on combination antiretroviral therapy. AIDS. 2021; 36(1):19-27. PMC: 8665003. DOI: 10.1097/QAD.0000000000003071. View

15.

Hakkers C, Arends J, van den Berk G, Ensing M, Hooijenga I, Vink M . Objective and Subjective Improvement of Cognition After Discontinuing Efavirenz in Asymptomatic Patients: A Randomized Controlled Trial. J Acquir Immune Defic Syndr. 2018; 80(1):e14-e22. DOI: 10.1097/QAI.0000000000001876. View

16.

Syed M, Fletcher A, Dweck M, Forsythe R, Newby D . Imaging aortic wall inflammation. Trends Cardiovasc Med. 2019; 29(8):440-448. PMC: 6853180. DOI: 10.1016/j.tcm.2018.12.003. View

17.

Alford K, Banerjee S, Daley S, Hamlyn E, Trotman D, Vera J . Health-Related Quality of Life in People Living With HIV With Cognitive Symptoms: Assessing Relevant Domains and Associations. J Int Assoc Provid AIDS Care. 2023; 22:23259582231164241. PMC: 10034276. DOI: 10.1177/23259582231164241. View

18.

Henderson M, Pepper N, Bawa M, Muir D, Everitt A, Mackie N . Cerebrospinal fluid virology in people with HIV. HIV Med. 2023; 24(7):838-844. DOI: 10.1111/hiv.13471. View

19.

Ferretti F, Mora-Peris B, Underwood J, Waldman A, Everitt A, Winston A . Cognitive Impairment in a Clinical Setting. J Acquir Immune Defic Syndr. 2017; 77(1):e10-e13. DOI: 10.1097/QAI.0000000000001547. View

20.

Ford N, Shubber Z, Pozniak A, Vitoria M, Doherty M, Kirby C . Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis of Randomized Trials. J Acquir Immune Defic Syndr. 2015; 69(4):422-9. DOI: 10.1097/QAI.0000000000000606. View